Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
11.46 USD -0.35% Intraday chart for Evolus, Inc. -0.87% +8.83%
Apr. 17 Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau CI
Apr. 03 Evolus, Inc. Announces Board Changes CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
EVOLUS, INC. Stock Evolus, Inc.
+8.83% 707M
D+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.95% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 219B
B+
NOVARTIS AG Stock Novartis AG
+6.04% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.51% 196B
A+
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 149B
C+
AMGEN INC. Stock Amgen Inc.
-6.47% 146B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. Ratings Evolus, Inc.